Survey of oncologists finds knowledge gap on medical marijuana
As more states legalize medical marijuana, two key groups — researchers whose job is it to understand its benefits and drawbacks, and physicians charged with advising potential users — are struggling to catch up with policymakers.
Ilana Braun, an assistant professor of psychiatry at Harvard Medical School and chief of the division of adult psychosocial oncology at the Dana-Farber Cancer Institute, led a survey of cancer physicians around the country, exploring their attitudes and actions on medical marijuana.
The survey was sent to 400 oncologists, with a 63 percent response rate. We asked Braun to outline her findings, which were published last month in the Journal of Clinical Oncology.
Stories you may be interested in
How Medical Marijuana Affects Men vs. Women
As expected, men and women differ in a multitude of ways, from genetic makeup and hormonal behavior to how we process information and emotionally respond. The differences in our makeup are the exact reason why any medical treatment, including medical marijuana, will have a diverse impact on men vs. women. Let’s take a closer look…
Read More 
Arfinn Med March Updates
We are very happy to announce the release of several new functions within the Arfinn Med Platform. Those include: * Text message updates from patients regarding their treatments * Templating for exam notes * Updated analytics and dosing reports * Google calendar and Calendly integrations to schedule appointments. Please view the video below for more…
Read More 
Military Times: “Our veterans deserve the well-being that medical cannabis can provide.”
The physical and mental trauma that veterans experience as a result of their military service extends far beyond the end of their participation in combat-related roles. To recognize the sacrifices veterans have made to protect our country, state and federal lawmakers must continue to expand access to crucial treatment options and programs that assist veterans…
Read More 
Cannabis and Seniors
As more and more research comes out regarding the medical benefits of cannabis, it’s important to keep up with new research as it becomes available. Here at Arfinn Med, we constantly review new studies and look at our own deidentified efficacy data to try to find any additional insights we can relay to our registered…
Read More 
Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease
A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More 
New Feature: Text Message Treatment Updates
New to the Arfinn Med portal comes the ability to receive real time updates from patients via text messaging. This new addition will allow physicians to stay up to date on current patient efficacies as well as streamline the data collection process. Through the new text messaging function, physicians are able to send patients automated…
Read More